Clinical trial

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

NCT04663997

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention 177Lu-PSMA-617 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-08-11

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

177Lu-PSMA-617DRUG

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Canadian Cancer Trials Grouplead sponsor

Prostate Cancer Canadacollaborator

Novartis Pharmaceuticalscollaborator

Mapped research locations

TorontoOntario, Canada2 MontrealQuebec, Canada2 VancouverBritish Columbia, Canada1 EdmontonAlberta, Canada1 LondonOntario, Canada1 CalgaryAlberta, Canada1 QuébecQuebec, Canada1 SherbrookeQuebec, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04663997 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.